Evidence map›Paper›PMID 40771923›Full record

ArticleFrontiers in pharmacology2025

CDFA: Calibrated deep feature aggregation for screening synergistic drug combinations.

Xiaorui Kang, Xiaoyan Liu, Quan Zou, Tiantian Li, Ximei Luo

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaorui KangFaculty of Applied Sciences, Macao Polytechnic University, Macau, China.
Xiaoyan LiuFaculty of Computing, Harbin Institute of Technology, Harbin, Heilongjiang, China.
Quan ZouFaculty of Applied Sciences, Macao Polytechnic University, Macau, China.
Tiantian LiEditorial Office, Geriatric Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Ximei LuoInstitute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Drug combination therapy represents a promising strategy for addressing complex diseases, offering the potential for improved efficacy while mitigating safety concerns. However, conventional wet-lab experimentation for identifying optimal drug combinations is resource-intensive due to the vast combinatorial search space. To address this challenge, computational methods leveraging machine learning and deep learning have emerged to effectively navigate this space. Methods: In this study, we introduce a Calibrated Deep Feature Aggregation (CDFA) framework for screening synergistic drug combinations. Concretely, CDFA utilizes a novel cell line representation based on the protein information and gene expression capturing complementary biological determinants of drug response. Besides, a novel feature aggregation network is proposed based on the Transformer to model the intricate interactions between drug pairs and cell lines through multi-head attention mechanisms, enabling discovery of non-linear synergy patterns. Furthermore, a method is introduced to quantify and calibrate the uncertainties associated with CDFA's predictions, enhancing the reliability of the identified synergistic drug combinations. Results: Experiments results have demonstrated that CDFA outperforms existing state-of-the-art deep learning models. Discussion: The superior performance of CDFA stems from its biologically informed cell line representation, its ability to capture complex non-linear drug-cell interactions via attention mechanisms, and its enhanced reliability through uncertainty calibration. This framework provides a robust computational tool for efficient and reliable drug combination screening.

Indexed as

deep learningdrug combinationfeature fusionsynergistic drugtransformer

Identifiers

PMID40771923
PMCPMC12325400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.